Related coverage linked through entity extraction aliases.
Jul 31, 2026
UVA Health found gliomas may be more receptive to focused ultrasound drug delivery. Related research covers miRNA therapy, low-intensity focused ultrasound, and 3D organoid drug testing.
Jun 08, 2026
A new "expand and pull" treatment strategy combines long-acting interleukin-7 and oncolytic virus therapy to boost T cell response in glioblastoma. In mouse models, the combination improved cytotoxic T cell function and led to long-term tumor-free survival.
May 07, 2026
Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
Mar 16, 2026
Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.
Feb 18, 2026
Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.
